FACULTY CHAIR
Chrysalyne D. Schmults, MD, MSCE
Associate Professor of Dermatology, Harvard Medical School
Vice-Chair of Surgical Oncology, Brigham and Women’s Department of Dermatology
Boston, MA
FACULTY PRESENTER
Anokhi Jambusaria, MD, MSCE
Assistant Professor, Department of Internal Medicine
Dell Medical School
The University of Texas at Austin
Austin, TX
Justin Leitenberger, MD
Assistant Professor of Dermatology
Oregon Health & Science University (OHSU)
Portland, OR
Emily Ruiz, MD, MPH
Associate Physician, Mohs and
Dermatologic Surgery Center
Dana-Farber/Brigham and Women’s Cancer Center
Instructor in Dermatology, Harvard Medical School
Director of the High-Risk Skin Cancer Clinic
Boston, MA
PROGRAM OVERVIEW
This enduring activity is a faculty-led didactic and case-based lecture focusing on treatment and management of patients with patients with advanced/metastatic basal cell skin cancer.
TARGET AUDIENCE
This activity is designed to meet the educational needs of medical oncologists, onco-dermatologists, dermatologists, Mohs surgeons, and other healthcare practitioners who care for patients with advanced/metastatic basal cell skin cancer.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
- Discuss the pathogenesis of metastatic BCC and the attendant involvement of both aberrant pathways and immune dysfunction
- Examine the epidemiology of basal cell carcinoma including prevalence, risk factors, and disease burden
- Apply NCCN practice guidelines for a multi-disciplinary approach to treatment of locally advanced and metastatic BCC
- Explore the clinical trial data for emerging immunotherapy agents in the treatment of advanced or metastatic basal cell skin cancer
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with advanced/metastatic basal cell skin cancer.
CNE Credits: 1.0 ANCC Contact Hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Chrysalyne D. Schmults, MD, MSCE receives consulting fees from Regeneron Pharmaceuticals and Sanofi. She serves as steering committee member for Castle Biosciences and Regeneron Pharmaceuticals; has received research funding from Castle Biosciences, Regeneron Pharmaceuticals, Novartis, Genentech, and Merck, and is a chair for NCCN.
Anokhi Jambusaria, MD, MSCE serves on the advisory board for Regeneron Pharmaceuticals.
Justin Leitenberger, MD has nothing to disclose.
Emily Ruiz, MD, MPH receives consulting fees from Sanofi, Pelle Pharm Inc., and Jounce Therapeutic. She discloses other commercial interests with Leo Pharma, Checkpoint Therapeutics, and Jounce Therapeutic.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Staff, Planners, and Managers
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Chris Drury, Medical Director for Med Learning Group, has nothing to disclose.
Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
Brianna Hanson, Outcomes and Accreditation Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
RELEASE DATE: April 2, 2021
EXPIRATION DATE: April 2, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
